STAT1 signaling is essential for protection against cryptococcus neoformans infection in mice

Journal of Immunology

Volumn 193, Issue 8, 2014, Pages 4060-4071

  Leopold Wager, Chrissy M ^a   Hole, Camaron R ^a   Wozniak, Karen L ^a   Olszewski, Michal A ^b,c   Wormley, Floyd L ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; STAT1 PROTEIN; STAT1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM INFECTION; CLEARANCE; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; CRYPTOCOCCUS NEOFORMANS STRAIN 52D; CRYPTOCOCCUS NEOFORMANS STRAIN H99GAMMA; FEMALE; FUNGAL BURDEN; FUNGAL STRAIN; GENE DELETION; IMMUNE RESPONSE; IMMUNOREGULATION; KNOCKOUT MOUSE; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE ACTIVATION; MORTALITY; MOUSE; MURINE MODEL; NONHUMAN; PATHOGEN CLEARANCE; PATHOGEN LOAD; PNEUMONIA; PROTECTION; PROTEIN ANALYSIS; PROTEIN FUNCTION; PULMONARY CRYPTOCOCCOSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE; TH1 CELL; TH2 CELL; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; GENETICS; IMMUNOLOGY; INFLAMMATION; LUNG MYCOSIS; MICROBIOLOGY; PHOSPHORYLATION;

ANIMALS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FEMALE; INFLAMMATION; LUNG DISEASES, FUNGAL; MACROPHAGE ACTIVATION; MACROPHAGES, ALVEOLAR; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NITRIC OXIDE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TH1 CELLS; TH2 CELLS;

EID: 84907486433     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400318     Document Type: Article

References (93)

1. Chuck, S. L., and M.A. Sande. 1989. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N. Engl. J. Med. 321: 794-799.
2. Dismukes, W. E. 1988. Cryptococcal meningitis in patients with AIDS. J. Infect. Dis. 157: 624-628.
3. Eng, R. H., E. Bishburg, S. M. Smith, and R. Kapila. 1986. Cryptococcal infections in patients with acquired immune deficiency syndrome. Am. J. Med. 81: 19-23.
4. Gal, A. A., M. N. Koss, J. Hawkins, S. Evans, and H. Einstein. 1986. The pathology of pulmonary cryptococcal infections in the acquired immunodeficiency syndrome. Arch. Pathol. Lab. Med. 110: 502-507.
5. Kovacs, J. A., A. A. Kovacs, M. Polis, W. C. Wright, V. J. Gill, C. U. Tuazon, E. P. Gelmann, H. C. Lane, R. Longfield, G. Overturf, et al. 1985. Cryptococcosis in the acquired immunodeficiency syndrome. Ann. Intern. Med. 103: 533-538.
6. Diamond, R. D., and J. E. Bennett. 1974. Prognostic factors in cryptococcal meningitis: a study in 111 cases. Ann. Intern. Med. 80: 176-181.
7. Duperval, R., P. E. Hermans, N. S. Brewer, and G. D. Roberts. 1977. Cryptococcosis, with emphasis on the significance of isolation of Cryptococcus neoformans from the respiratory tract. Chest 72: 13-19.
8. Goldstein, E., and O. N. Rambo. 1962. Cryptococcal infection following steroid therapy. Ann. Intern. Med. 56: 114-120.
9. Collins, V. P., A. Gellhorn, and J.R. Trimble. 1951. The coincidence of cryptococcosis and disease of the reticulo-endothelial and lymphatic systems. Cancer 4: 883-889.
10. Gendel, B. R., M. Ende, and S. L. Norman. 1950. Cryptococcosis; a review with special reference to apparent association with Hodgkin's disease. Am. J. Med. 9: 343-355.
11. Keye, J. D., Jr., and W. E. Magee. 1956. Fungal diseases in a general hospital; a study of 88 patients. Am. J. Clin. Pathol. 26: 1235-1253.
12. Lewis, J. L., and S. Rabinovich. 1972. The wide spectrum of cryptococcal infections. Am. J. Med. 53: 315-322.
13. Husain, S., M. M. Wagener, and N. Singh. 2001. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg. Infect. Dis. 7: 375-381.
14. Park, B. J., K. A. Wannemuehler, B. J. Marston, N. Govender, P. G. Pappas, and T. M. Chiller. 2009. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23: 525-530.
15. Singh, N., O. Lortholary, B. D. Alexander, K. L. Gupta, G. T. John, K. Pursell, P. Munoz, G. B. Klintmalm, V. Stosor, R. del Busto, et al. 2005. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin. Infect. Dis. 40: 1756-1761.
16. Pappas, P. G., B. D. Alexander, D. R. Andes, S. Hadley, C. A. Kauffman, A. Freifeld, E. J. Anaissie, L. M. Brumble, L. Herwaldt, J. Ito, et al. 2010. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin. Infect. Dis. 50: 1101-1111.
17. Coker, R. J., M. Viviani, B. G. Gazzard, B. Du Pont, H. D. Pohle, S. M. Murphy, J. Atouguia, J. L. Champalimaud, and J.R. Harris. 1993. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 7: 829-835.
18. Perfect, J.R., and G. M. Cox. 1999. Drug resistance in Cryptococcus neoformans. Drug Resist. Updat. 2: 259-269.
19. Roh, T. Y., S. Cuddapah, K. Cui, and K. Zhao. 2006. The genomic landscape of histone modifications in human T cells. Proc. Natl. Acad. Sci. USA 103: 15782-15787.
20. Mitchell, T. G., and J.R. Perfect. 1995. Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 8: 515-548.
21. Goldman, D. L., H. Khine, J. Abadi, D. J. Lindenberg, R. Pirofski La, Niang, and A. Casadevall. 2001. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 107: E66.
22. Abadi, J., S. Nachman, A. B. Kressel, and L. Pirofski. 1999. Cryptococcosis in children with AIDS. Clin. Infect. Dis. 28: 309-313.
23. Chayakulkeeree, M., and J.R. Perfect. 2006. Cryptococcosis. Infect. Dis. Clin. North Am. 20: 507-544, v-vi (v-vi.).
24. Hardison, S. E., G. Herrera, M. L. Young, C. R. Hole, K. L. Wozniak, and F. L. Wormley, Jr. 2012. Protective immunity against pulmonary cryptococcosis is associated with STAT1-mediated classical macrophage activation. J. Immunol. 189: 4060-4068.
25. Zhang, Y., F. Wang, K. C. Tompkins, A. McNamara, A. V. Jain, B. B. Moore, G. B. Toews, G. B. Huffnagle, and M.A. Olszewski. 2009. Robust Th1 and Th17 immunity supports pulmonary clearance but cannot prevent systemic dissemination of highly virulent Cryptococcus neoformans H99. Am. J. Pathol. 175: 2489-2500.
26. Hardison, S. E., S. Ravi, K. L. Wozniak, M. L. Young, M.A. Olszewski, and F. L. Wormley, Jr. 2010. Pulmonary infection with an interferon-g-producing Cryptococcus neoformans strain results in classical macrophage activation and protection. Am. J. Pathol. 176: 774-785.
27. Jain, A. V., Y. Zhang, W. B. Fields, D. A. McNamara, M. Y. Choe, G. H. Chen, J. Erb-Downward, J. J. Osterholzer, G. B. Toews, G. B. Huffnagle, and M.A. Olszewski. 2009. Th2 but not Th1 immune bias results in altered lung functions in a murine model of pulmonary Cryptococcus neoformans infection. Infect. Immun. 77: 5389-5399.
28. Herring, A. C., J. Lee, R. A. McDonald, G. B. Toews, and G. B. Huffnagle. 2002. Induction of interleukin-12 and g interferon requires tumor necrosis factor a for protective T1-cell-mediated immunity to pulmonary Cryptococcus neoformans infection. Infect. Immun. 70: 2959-2964.
29. Huffnagle, G. B., M. F. Lipscomb, J. A. Lovchik, K. A. Hoag, and N. E. Street. 1994. The role of CD4+ and CD8+ T cells in the protective inflammatory response to a pulmonary cryptococcal infection. J. Leukoc. Biol. 55: 35-42.
30. Huffnagle, G. B., G. B. Toews, M. D. Burdick, M. B. Boyd, K. S. McAllister, R. A. McDonald, S. L. Kunkel, and R. M. Strieter. 1996. Afferent phase production of TNF-a is required for the development of protective T cell immunity to Cryptococcus neoformans. J. Immunol. 157: 4529-4536.
31. Arora, S., Y. Hernandez, J.R. Erb-Downward, R. A. McDonald, G. B. Toews, and G. B. Huffnagle. 2005. Role of IFN-γ in regulating T2 immunity and the development of alternatively activated macrophages during allergic bronchopulmonary mycosis. J. Immunol. 174: 6346-6356.
32. Chen, G. H., D. A. McNamara, Y. Hernandez, G. B. Huffnagle, G. B. Toews, and M.A. Olszewski. 2008. Inheritance of immune polarization patterns is linked to resistance versus susceptibility to Cryptococcus neoformans in a mouse model. Infect. Immun. 76: 2379-2391.
33. Hernandez, Y., S. Arora, J.R. Erb-Downward, R. A. McDonald, G. B. Toews, and G. B. Huffnagle. 2005. Distinct roles for IL-4 and IL-10 in regulating T2 immunity during allergic bronchopulmonary mycosis. J. Immunol. 174: 1027-1036.
34. Mosser, D. M., and J. P. Edwards. 2008. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8: 958-969.
35. Müller, U., W. Stenzel, G. Köhler, C. Werner, T. Polte, G. Hansen, N. Schütze, R. K. Straubinger, M. Blessing, A. N. McKenzie, et al. 2007. IL-13 induces disease-promoting type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with Cryptococcus neoformans. J. Immunol. 179: 5367-5377.
36. Osterholzer, J. J., R. Surana, J. E. Milam, G. T. Montano, G. H. Chen, J. Sonstein, J. L. Curtis, G. B. Huffnagle, G. B. Toews, and M.A. Olszewski. 2009. Cryptococcal urease promotes the accumulation of immature dendritic cells and a non-protective T2 immune response within the lung. Am. J. Pathol. 174: 932-943.
37. Hesse, M., M. Modolell, A. C. La Flamme, M. Schito, J. M. Fuentes, A. W. Cheever, E. J. Pearce, and T. A. Wynn. 2001. Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism. J. Immunol. 167: 6533-6544.
38. Granger, D. L., J. B. Hibbs, Jr., J.R. Perfect, and D. T. Durack. 1988. Specific amino acid (L-arginine) requirement for the microbiostatic activity of murine macrophages. J. Clin. Invest. 81: 1129-1136.
39. Granger, D. L., J. B. Hibbs, Jr., J.R. Perfect, and D. T. Durack. 1990. Metabolic fate of L-arginine in relation to microbiostatic capability of murine macrophages. J. Clin. Invest. 85: 264-273.
40. Chen, G. H., M.A. Olszewski, R. A. McDonald, J. C. Wells, R. Paine, III, G. B. Huffnagle, and G. B. Toews. 2007. Role of granulocyte macrophage colony-stimulating factor in host defense against pulmonary Cryptococcus neoformans infection during murine allergic bronchopulmonary mycosis. Am. J. Pathol. 170: 1028-1040.
41. Guerrero, A., N. Jain, X. Wang, and B. C. Fries. 2010. Cryptococcus neoformans variants generated by phenotypic switching differ in virulence through effects on macrophage activation. Infect. Immun. 78: 1049-1057.
42. Hardison, S. E., K. L.Wozniak, J. K. Kolls, and F. L.Wormley, Jr. 2010. Interleukin- 17 is not required for classical macrophage activation in a pulmonary mouse model of Cryptococcus neoformans infection. Infect. Immun. 78: 5341-5351.
43. Stark, G. R. 2007. How cells respond to interferons revisited: from early history to current complexity. Cytokine Growth Factor Rev. 18: 419-423.
44. Szabo, S. J., B. M. Sullivan, S. L. Peng, and L. H. Glimcher. 2003. Molecular mechanisms regulating Th1 immune responses. Annu. Rev. Immunol. 21: 713-758.
45. Taki, S., T. Sato, K. Ogasawara, T. Fukuda, M. Sato, S. Hida, G. Suzuki, M. Mitsuyama, E. H. Shin, S. Kojima, et al. 1997. Multistage regulation of Th1- type immune responses by the transcription factor IRF-1. Immunity 6: 673-679.
46. Mikhak, Z., C. M. Fleming, B. D. Medoff, S. Y. Thomas, A. M. Tager, G. S. Campanella, and A. D. Luster. 2006. STAT1 in peripheral tissue differentially regulates homing of antigen-specific Th1 and Th2 cells. J. Immunol. 176: 4959-4967.
47. Smeekens, S. P., T. S. Plantinga, F. L. van de Veerdonk, B. Heinhuis, A. Hoischen, L. A. Joosten, P. D. Arkwright, A. Gennery, B. J. Kullberg, J. A. Veltman, et al. 2011. STAT1 hyperphosphorylation and defective IL12R/ IL23R signaling underlie defective immunity in autosomal dominant chronic mucocutaneous candidiasis. PLoS One 6: e29248.
48. van de Veerdonk, F. L., T. S. Plantinga, A. Hoischen, S. P. Smeekens, L. A. Joosten, C. Gilissen, P. Arts, D. C. Rosentul, A. J. Carmichael, C. A. Smitsvan der Graaf, et al. 2011. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N. Engl. J. Med. 365: 54-61.
49. Sampaio, E. P., A. P. Hsu, J. Pechacek, H. I. Bax, D. L. Dias, M. L. Paulson, P. Chandrasekaran, L. B. Rosen, D. S. Carvalho, L. Ding, et al. 2013. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J. Allergy Clin. Immunol. 131: 1624-1634 e1617.
50. Wormley, F. L., Jr., J.R. Perfect, C. Steele, and G. M. Cox. 2007. Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain. Infect. Immun. 75: 1453-1462.
51. Wozniak, K. L., S. Ravi, S. Macias, M. L. Young, M.A. Olszewski, C. Steele, and F. L. Wormley. 2009. Insights into the mechanisms of protective immunity against Cryptococcus neoformans infection using a mouse model of pulmonary cryptococcosis. PLoS One 4: e6854.
52. Wozniak, K. L., M. L. Young, and F. L. Wormley, Jr. 2011. Protective immunity against experimental pulmonary cryptococcosis in T cell-depleted mice. Clin. Vaccine Immunol. 18: 717-723.
53. Huffnagle, G. B., J. L. Yates, and M. F. Lipscomb. 1991. Immunity to a pulmonary Cryptococcus neoformans infection requires both CD4+ and CD8+ T cells. J. Exp. Med. 173: 793-800.
54. Arora, S., M.A. Olszewski, T. M. Tsang, R. A. McDonald, G. B. Toews, and G. B. Huffnagle. 2011. Effect of cytokine interplay on macrophage polarization during chronic pulmonary infection with Cryptococcus neoformans. Infect. Immun. 79: 1915-1926.
55. Cox, G. M., T. S. Harrison, H. C. McDade, C. P. Taborda, G. Heinrich, A. Casadevall, and J.R. Perfect. 2003. Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages. Infect. Immun. 71: 173-180.
56. Wormley, F. L., Jr., G. Heinrich, J. L. Miller, J.R. Perfect, and G. M. Cox. 2005. Identification and characterization of an SKN7 homologue in Cryptococcus neoformans. Infect. Immun. 73: 5022-5030.
57. Giles, S. S., J. E. Stajich, C. Nichols, Q. D. Gerrald, J. A. Alspaugh, F. Dietrich, and J.R. Perfect. 2006. The Cryptococcus neoformans catalase gene family and its role in antioxidant defense. Eukaryot. Cell 5: 1447-1459.
58. de Jesús-Berríos, M., L. Liu, J. C. Nussbaum, G. M. Cox, J. S. Stamler, and J. Heitman. 2003. Enzymes that counteract nitrosative stress promote fungal virulence. Curr. Biol. 13: 1963-1968.
59. Aguirre, K. M., and G. W. Gibson. 2000. Differing requirement for inducible nitric oxide synthase activity in clearance of primary and secondary Cryptococcus neoformans infection. Med. Mycol. 38: 343-353.
60. Lovchik, J. A., C. R. Lyons, and M. F. Lipscomb. 1995. A role for g interferoninduced nitric oxide in pulmonary clearance of Cryptococcus neoformans. Am. J. Respir. Cell Mol. Biol. 13: 116-124.
61. Meraz, M.A., J. M. White, K. C. Sheehan, E. A. Bach, S. J. Rodig, A. S. Dighe, D. H. Kaplan, J. K. Riley, A. C. Greenlund, D. Campbell, et al. 1996. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84: 431-442.
62. Saha, B., S. Jyothi Prasanna, B. Chandrasekar, and D. Nandi. 2010. Gene modulation and immunoregulatory roles of interferon γ. Cytokine 50: 1-14.
63. Kernbauer, E., V. Maier, D. Stoiber, B. Strobl, C. Schneckenleithner, V. Sexl, U. Reichart, B. Reizis, U. Kalinke, A. Jamieson, et al. 2012. Conditional Stat1 ablation reveals the importance of interferon signaling for immunity to Listeria monocytogenes infection. PLoS Pathog. 8: e1002763.
64. Lang, C., A. Hildebrandt, F. Brand, L. Opitz, H. Dihazi, and C. G. Lüder. 2012. Impaired chromatin remodelling at STAT1-regulated promoters leads to global unresponsiveness of Toxoplasma gondii-infected macrophages to IFN-γ. PLoS Pathog. 8: e1002483.
65. Gavrilescu, L. C., B. A. Butcher, L. Del Rio, G. A. Taylor, and E. Y. Denkers. 2004. STAT1 is essential for antimicrobial effector function but dispensable for gamma interferon production during Toxoplasma gondii infection. Infect. Immun. 72: 1257-1264.
66. Lieberman, L. A., M. Banica, S. L. Reiner, and C. A. Hunter. 2004. STAT1 plays a critical role in the regulation of antimicrobial effector mechanisms, but not in the development of Th1-type responses during toxoplasmosis. J. Immunol. 172: 457-463.
67. + T cells. Nat. Immunol. 3: 549-557.
68. Lighvani, A. A., D. M. Frucht, D. Jankovic, H. Yamane, J. Aliberti, B. D. Hissong, B. V. Nguyen, M. Gadina, A. Sher, W. E. Paul, and J. J. O'Shea. 2001. T-bet is rapidly induced by interferon-g in lymphoid and myeloid cells. Proc. Natl. Acad. Sci. USA 98: 15137-15142.
69. Usui, T., J. C. Preiss, Y. Kanno, Z. J. Yao, J. H. Bream, J. J. O'Shea, and W. Strober. 2006. T-bet regulates Th1 responses through essential effects on GATA-3 function rather than on IFNG gene acetylation and transcription. J. Exp. Med. 203: 755-766.
70. Hwang, E. S., S. J. Szabo, P. L. Schwartzberg, and L. H. Glimcher. 2005. T helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3. Science 307: 430-433.
71. Zheng, W., and R. A. Flavell. 1997. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 89: 587-596.
72. Zhang, D. H., L. Cohn, P. Ray, K. Bottomly, and A. Ray. 1997. Transcription factor GATA-3 is differentially expressed in murine Th1 and Th2 cells and controls Th2-specific expression of the interleukin-5 gene. J. Biol. Chem. 272: 21597-21603.
73. Starr, R., T. A. Willson, E. M. Viney, L. J. Murray, J.R. Rayner, B. J. Jenkins, T. J. Gonda, W. S. Alexander, D. Metcalf, N. A. Nicola, and D. J. Hilton. 1997. A family of cytokine-inducible inhibitors of signalling. Nature 387: 917-921.
74. Alexander, W. S., R. Starr, J. E. Fenner, C. L. Scott, E. Handman, N. S. Sprigg, J. E. Corbin, A. L. Cornish, R. Darwiche, C. M. Owczarek, et al. 1999. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98: 597-608.
75. Müller, M., S. Carter, M. J. Hofer, and I. L. Campbell. 2010. Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity - α tale of conflict and conundrum. Neuropathol. Appl. Neurobiol. 36: 368-387.
76. Hidore, M. R., and J. W. Murphy. 1986. Natural cellular resistance of beige mice against Cryptococcus neoformans. J. Immunol. 137: 3624-3631.
77. Lipscomb, M. F., T. Alvarellos, G. B. Toews, R. Tompkins, Z. Evans, G. Koo, and V. Kumar. 1987. Role of natural killer cells in resistance to Cryptococcus neoformans infections in mice. Am. J. Pathol. 128: 354-361.
78. Fulkerson, P. C., N. Zimmermann, E. B. Brandt, E. E. Muntel, M. P. Doepker, J. L. Kavanaugh, A. Mishra, D. P. Witte, H. Zhang, J. M. Farber, et al. 2004. Negative regulation of eosinophil recruitment to the lung by the chemokine monokine induced by IFN-γamma (Mig, CXCL9). Proc. Natl. Acad. Sci. USA 101: 1987-1992.
79. Fulkerson, P. C., H. Zhu, D. A. Williams, N. Zimmermann, and M. E. Rothenberg. 2005. CXCL9 inhibits eosinophil responses by a CCR3- and Rac2-dependent mechanism. Blood 106: 436-443.
80. Casadevall, A., and L. A. Pirofski. 2009. Virulence factors and their mechanisms of action: the view from a damage-response framework. J. Water Health 7(Suppl. 1): S2-S18.
81. Pirofski, L. A., and A. Casadevall. 2008. The damage-response framework of microbial pathogenesis and infectious diseases. Adv. Exp. Med. Biol. 635: 135-146.
82. Stenzel, W., U. Müller, G. Köhler, F. L. Heppner, M. Blessing, A. N. McKenzie, F. Brombacher, and G. Alber. 2009. IL-4/IL-13-dependent alternative activation of macrophages but not microglial cells is associated with uncontrolled cerebral cryptococcosis. Am. J. Pathol. 174: 486-496.
83. Davis, M. J., T. M. Tsang, Y. Qiu, J. K. Dayrit, J. B. Freij, G. B. Huffnagle, and M.A. Olszewski. 2013. Macrophage M1/M2 polarization dynamically adapts to changes in cytokine microenvironments in Cryptococcus neoformans infection. MBio 4: e00264-e13.
84. Youseff, B. H., E. D. Holbrook, K. A. Smolnycki, and C. A. Rappleye. 2012. Extracellular superoxide dismutase protects Histoplasma yeast cells from hostderived oxidative stress. PLoS Pathog. 8: e1002713.
85. Newman, S. L., L. Gootee, J. Hilty, and R. E. Morris. 2006. Human macrophages do not require phagosome acidification to mediate fungistatic/fungicidal activity against Histoplasma capsulatum. J. Immunol. 176: 1806-1813.
86. Newman, S. L. 1999. Macrophages in host defense against Histoplasma capsulatum. Trends Microbiol. 7: 67-71.
87. Allen, H. L., and G. S. Deepe, Jr. 2005. Apoptosis modulates protective immunity to the pathogenic fungus Histoplasma capsulatum. J. Clin. Invest. 115: 2875-2885.
88. Moreira, A. P., K. A. Cavassani, R. Hullinger, R. S. Rosada, D. J. Fong, L. Murray, D. P. Hesson, and C. M. Hogaboam. 2010. Serum amyloid P attenuates M2 macrophage activation and protects against fungal spore-induced allergic airway disease. J. Allergy Clin. Immunol. 126: 712-721 e717.
89. Brummer, E., N. Kethineni, and D. A. Stevens. 2005. Immunological basis for susceptibility and resistance to pulmonary blastomycosis in mouse strains. Cytokine 32: 12-19.
90. Brummer, E., L. H. Hanson, A. Restrepo, and D. A. Stevens. 1988. In vivo and in vitro activation of pulmonary macrophages by IFN-γ for enhanced killing of Paracoccidioides brasiliensis or Blastomyces dermatitidis. J. Immunol. 140: 2786-2789.
91. Rocco, N. M., J. C. Carmen, and B. S. Klein. 2011. Blastomyces dermatitidis yeast cells inhibit nitric oxide production by alveolar macrophage inducible nitric oxide synthase. Infect. Immun. 79: 2385-2395.
92. Moreira, A. P., L. A. Dias-Melicio, M. T. Peraçoli, S. A. Calvi, and A. M. Victoriano de Campos Soares. 2008. Killing of Paracoccidioides brasiliensis yeast cells by IFN-γ and TNF-α activated murine peritoneal macrophages: evidence of H2O2 and NO effector mechanisms. Mycopathologia 166: 17-23.
93. Brummer, E., L. H. Hanson, and D. A. Stevens. 1988. γ-Interferon activation of macrophages for killing of Paracoccidioides brasiliensis and evidence for nonoxidative mechanisms. Int. J. Immunopharmacol. 10: 945-952.